Premium
Mafosfamide (ASTA‐Z‐7654) in vitro treatment of bone marrow does not eradicate Philadelphia‐positive cells in chronic myeloid leukaemia
Author(s) -
Mortensen B. T.,
Ernst P.,
Philip P.
Publication year - 1988
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1988.tb01184.x
Subject(s) - bone marrow , chronic myeloid leukaemia , medicine , in vitro , myeloid , myeloid leukemia , immunology , cancer research , chemistry , biochemistry
Bone marrow from 9 patients with Ph 1 + CML was treated in vitro with varying concentrations of Mafosfamide in order to test the hypothesis that selective pharmacological killing of Ph 1 ‐positive cells in CML is feasible. A marked difference in sensitivity to Mafosfamide of CFU‐GM was observed, but at all concentrations 100% persistence of Ph 1 + cells was noticed. We conclude that, in classical cases of Ph 1 ‐positive CML, Mafosfamide purging of bone marrow will not be effective.